CYTK logo

CYTK Cytokinetics, Incorporated

NASDAQ · Biotechnology · Healthcare

$50.78
-0.68 (-1.32%)

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral,…

Market Cap: $7.07Bwww.cytokinetics.com

Price

No data yet.

Social Signal Score

52
5d
—
30d
51
12 mentions
—
60d
53
20 mentions
—
90d
53
33 mentions
—
news: 27 · rss: 5 · marketaux: 1

Analyst Ratings

35 analysts
Buyconsensus
Strong Buy 0Buy 34Hold 1Sell 0Strong Sell 0
Avg price target$107.14+111.0%
Low $81Median $112High $118
Current Consensus

Revenue

$47.56M+43.51%
$-18.0K$29.64M$59.31M$88.97M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-6.49
$-7.02–$-6.11
10 analysts
FY2026
$-6.00
$-6.24–$-4.16
16 analysts
FY2027
$-4.25
$-5.80–$-2.89
16 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Robert I. Blum
Sector
Healthcare
Industry
Biotechnology
Employees
673
Beta
0.36
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-1.82
www.cytokinetics.com